Literature DB >> 7875840

Treatment of nephrotic syndrome.

S Gulati1, V Kher, R Elhence, P Kumar, R K Sharma, A Gupta.   

Abstract

There are well defined therapeutic protocols for childhood nephrotic syndrome. Appropriate therapy helps in minimizing side effects besides decreasing referrals to tertiary care centres. We have analysed the appropriateness of therapy of primary care physicians in 111 children with nephrotic syndrome referred to our Institute from January 1989 to December 1991. Prednisone was administered in adequate doses in 51 (52.6%), and for adequate duration in 41 children (42.2%). Adjunctive cyclophosphamide therapy was administered in the recommended doses and duration in 33% of the cases. On evaluation of the therapy it was observed that inappropriate treatment had been administered by 39.4% of the pediatricians, 59% of internists and 80% of general practitioners. This study highlights the lacunae in the current state of knowledge amongst the primary physicians and highlights the need for creating greater awareness regarding the therapy of children with nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7875840

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  3 in total

1.  Is typing for HLA class II alleles beneficial in Indian children with idiopathic nephrotic syndrome?

Authors:  Sanjeev Gulati; Piyush Tripathi; Siddramappa J Patil; Raj Kumar Sharma; Suraksha Agarwal
Journal:  Pediatr Nephrol       Date:  2006-12-16       Impact factor: 3.714

2.  Do glutathione-S-transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome?

Authors:  Sheetal V Sharda; Sanjeev Gulati; Gaurav Tripathi; Tabrez Jafar; Alok Kumar; Raj Kumar Sharma; Suraksha Agrawal
Journal:  Pediatr Nephrol       Date:  2008-07-02       Impact factor: 3.714

3.  Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome.

Authors:  Narayan Prasad; Sanjeev Gulati; Raj Kumar Sharma; Uttam Singh; Muffazal Ahmed
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.